Impact on Healthcare

Saving lives
in resistant times

Antimicrobial Resistance (AMR) is the silent pandemic that threatens our global healthcare systems and well-being in an unprecedented manner. At BioVersys, we fight AMR using innovation to save lives and improve patient outcomes. The Covid-19 global pandemic has highlighted the devastating impact of one infectious disease, let alone the potential simultaneous emergence of multiple pathogens that are already widespread in our communities.

Antimicrobial Resistance
ECCMID 2021

BioVersys presents latest pipeline developments at ECCMID

BioVersys is presenting the latest data from its innovative antimicrobial pipeline with three oral and six poster presentations at ECCMID.
The silent pandemic…
The global impact of Antimicrobial Resistance
on people is huge
700’000
die each year from drug resistant infections
10 million
annual deaths by 2050 if no action taken
13.5 US$ billion
annual financial loss in US & EU due to hospital infections

Identifying unmet medical needs

Making people’s lives better

In March 1942, Anne Miller was near death. Infectious germs had made their way into her bloodstream. Doctors administered an experimental drug to her – Penicillin – and she recovered. She became the first person in the world to be saved by an antibiotic. Unfortunately, germs like the one that infected Anne Miller are becoming or have become resistant to antibiotics. Over the last few decades, we have seen limited to no progress in the introduction of new antibiotics. This is a ticking time bomb that threatens the world’s healthcare systems and endanger lives.

Rich and diverse pipeline

Impactful solutions for AMR

Lead optimization
Preclinical
Phase 1
Phase 2/3
Partners
BV100 – novel MoA

Serious hospital infections -
A. baumannii

Lead optimization
Preclinical
Phase 1
Phase 2/3
BVL-GSK098 – novel potentiator MoA

MDR-TB

Lead optimization
Preclinical
Phase 1
Phase 2/3
BV200 – novel anti-virulence MoA

(1) Community and hospital infections Staph. aureus
(2) Atopic dermatitis

Lead optimization
Preclinical
Phase 1
Phase 2/3
1
2
BV300 - novel class

ESKAPE pathogens

Lead optimization
Preclinical
Phase 1
Phase 2/3

About us

Who we are

We are a passionate team, fighting against bacterial infections by focusing on research and development of small molecules that work by novel modes of action and against novel targets. BioVersys is an award winning privately-owned Swiss pharmaceutical company headquartered in Basel, Switzerland.

Newsroom

Latest News

View all News
News | 06.07.21
BioVersys presents latest data on clinical pipeline at ECCMID 2021
News | 05.07.21
BIOVERSYS APPOINTS MEDICAL DIRECTOR AND HEAD OF CMC
News | 01.06.21
BIOVERSYS RECEIVES A SECOND CARB-X AWARD OF UP TO US$ 15.34 MILLION FOR BV300